0.78
+0.0358(+4.82%)
Currency In USD
| Previous Close | 0.74 |
| Open | 0.7 |
| Day High | 0.84 |
| Day Low | 0.65 |
| 52-Week High | 66.33 |
| 52-Week Low | 0.65 |
| Volume | 12.6M |
| Average Volume | 2.44M |
| Market Cap | 541,542 |
| PE | 0 |
| EPS | 5,571.72 |
| Moving Average 50 Days | 5.4 |
| Moving Average 200 Days | 14.94 |
| Change | 0.04 |
If you invested $1000 in TransCode Therapeutics, Inc. (RNAZ) since IPO date, it would be worth $0.01 as of March 15, 2025 at a share price of $0.778. Whereas If you bought $1000 worth of TransCode Therapeutics, Inc. (RNAZ) shares 3 years ago, it would be worth $0.01 as of March 15, 2025 at a share price of $0.778.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
GlobeNewswire Inc.
Nov 29, 2024 9:25 PM GMT
BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
GlobeNewswire Inc.
Nov 27, 2024 12:00 PM GMT
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a securities purchase ag
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
GlobeNewswire Inc.
Nov 25, 2024 12:00 PM GMT
Split designed to achieve compliance with Nasdaq minimum bid price requirementsBOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effecti